Related Experiment Video

Updated: Jul 5, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

RhoC a new target for therapeutic vaccination against metastatic cancer

Lynn Wenandy1, Rikke Baek Sørensen, Inge Marie Svane

  • 1Center for Cancer Immune therapy (CCIT), Department of Hematology, Herlev University Hospital, 2730, Herlev, Denmark.

Cancer Immunology, Immunotherapy : CII
|April 17, 2008
PubMed

Insights

RhoC protein, often overexpressed in cancers, is a promising target for immunotherapy. Researchers identified a specific RhoC epitope that activates cytotoxic T cells, offering a new strategy to combat cancer metastasis.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Metastasis is a primary cause of cancer mortality.
  • RhoC protein overexpression correlates with increased metastatic potential across various cancers.
  • Targeting RhoC presents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To identify and characterize a RhoC-derived epitope for anti-cancer immunotherapy.
  • To evaluate the efficacy of T cells recognizing this RhoC epitope against cancer cells.

Main Methods:

  • Identification of an HLA-A3 restricted epitope from RhoC.
  • Generation and characterization of RhoC-specific cytotoxic T cells.
  • Assessment of T cell cytotoxicity against HLA-matched cancer cell lines of diverse origins.

Main Results:

  • An HLA-A3 restricted epitope from RhoC was identified.
  • RhoC-specific T cells demonstrated cytotoxic activity against relevant cancer cells.
  • This suggests RhoC can be a target for broad anti-cancer immunotherapeutic strategies.

Conclusions:

  • RhoC is a viable and broadly applicable target for anti-cancer immunotherapy.
  • The identified RhoC epitope can be utilized to develop T cell-based cancer therapies.
  • Targeting RhoC may reduce cancer morbidity and mortality by preventing immune escape.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...